Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates insulin secretion and inhibits glucagon s...

Full description

Bibliographic Details
Main Author: Ahren B
Format: Article
Language:English
Published: Dove Medical Press 2010-03-01
Series:Diabetes, Metabolic Syndrome and Obesity
Subjects:
Glucagon-like peptide-1
dipeptidyl peptidase-4
type 2 diabetes
sitagliptin
treatment
Online Access:https://www.dovepress.com/use-of-dpp-4-inhibitors-in-type-2-diabetes-focus-on-sitagliptin-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/use-of-dpp-4-inhibitors-in-type-2-diabetes-focus-on-sitagliptin-peer-reviewed-article-DMSO

Similar Items